| 000 | 01165 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250517215030.0 | ||
| 264 | 0 | _c20190618 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a1365-2133 | ||
| 024 | 7 |
_a10.1111/bjd.16785 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWan, M T | |
| 245 | 0 | 0 |
_aNivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal: ORIGINAL ARTICLE: Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377:1345-56. _h[electronic resource] |
| 260 |
_bThe British journal of dermatology _c08 2018 |
||
| 300 |
_a296-300 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAntibodies, Monoclonal |
| 650 | 0 | 4 | _aAntineoplastic Combined Chemotherapy Protocols |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIpilimumab |
| 650 | 0 | 4 | _aMelanoma |
| 650 | 0 | 4 | _aNivolumab |
| 700 | 1 | _aMing, M E | |
| 773 | 0 |
_tThe British journal of dermatology _gvol. 179 _gno. 2 _gp. 296-300 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bjd.16785 _zAvailable from publisher's website |
| 999 |
_c28396290 _d28396290 |
||